[
    [
        {
            "time": "",
            "original_text": "医药生物行业跨市场周报：2020年医保谈判结束 BIOTECH和创新药路在何方？",
            "features": {
                "keywords": [
                    "医保谈判",
                    "BIOTECH",
                    "创新药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：2020年医保谈判结束 BIOTECH和创新药路在何方？",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：参股子公司天津有济医药拟引入产业资本增资扩股",
            "features": {
                "keywords": [
                    "凯莱英",
                    "天津有济医药",
                    "增资扩股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：参股子公司天津有济医药拟引入产业资本增资扩股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：天津有济医药获海河凯莱英基金投资2250万元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "天津有济医药",
                    "海河凯莱英基金",
                    "投资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：天津有济医药获海河凯莱英基金投资2250万元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)拟回购注销2020年限制性股票激励计划4万股限制性股票",
            "features": {
                "keywords": [
                    "凯莱英",
                    "回购注销",
                    "限制性股票"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)拟回购注销2020年限制性股票激励计划4万股限制性股票",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本重仓A股八大将 持仓股有何优势基因？",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "A股",
                    "持仓股",
                    "优势基因"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "多行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本重仓A股八大将 持仓股有何优势基因？",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业报告：医保谈判落地不确定性消除 加大医药优质赛道关注度",
            "features": {
                "keywords": [
                    "医保谈判",
                    "不确定性消除",
                    "优质赛道"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业报告：医保谈判落地不确定性消除 加大医药优质赛道关注度",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：“三重行业红利 五重公司催化”助推智飞生物 强调Q1医药躁动机会",
            "features": {
                "keywords": [
                    "三重行业红利",
                    "五重公司催化",
                    "智飞生物",
                    "Q1医药躁动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：“三重行业红利 五重公司催化”助推智飞生物 强调Q1医药躁动机会",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "炒股抄高瓴作业？跟买爱尔眼科3年收益率482% 有只股却赔26%",
            "features": {
                "keywords": [
                    "高瓴",
                    "爱尔眼科",
                    "收益率",
                    "亏损"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "both"
            },
            "scores": {
                "News_content": "炒股抄高瓴作业？跟买爱尔眼科3年收益率482% 有只股却赔26%",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]